Published on 28 Jan 2024 on Simply Wall St. via Yahoo Finance
Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 42% Undervaluation?
Key Insights
Using the 2 Stage Free Cash Flow to Equity, Kura Oncology fair value estimate is US$33.82Kura Oncology is estimated to be 42% undervalued based on current share price of US$19.61 The US$28.29 analyst price target for KURA is 16% less than our estimate of fair value
How far off is Kura Oncology, Inc. (NASDAQ:KURA) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows and then discounting them to today's value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. Don't get put off by the jargon, the math behind it is actually quite straightforward.